Brooke Story Biography and Net Worth

Director of LivaNova

Brooke Story serves as Integration Lead at Becton, Dickinson and Company, a position she assumed in June 2024. She previously served as the Worldwide President, Surgery at Becton, Dickinson and Company from July 2023 to March 2024 and Worldwide President, Integrated Diagnostics Solutions at Becton, Dickinson and Company from April 2021 to July 2023. Prior to that, Ms. Story spent 15 years at Medtronic, where she held a variety of roles in finance, sales, and business unit leadership, culminating in her tenure as President, Pelvic Health and Gastric Therapies. Ms. Story began her career in sales at Johnson & Johnson and as a consultant for Accenture. Ms. Story holds a BS in industrial engineering from the University of Tennessee and an MBA from the University of Michigan.

Ms. Story is a seasoned senior executive with expertise in international business strategy and operations in the highly regulated medical technology industry. Throughout her career, she has excelled in helping large medical device corporations inspire teams, mentor and develop talent, and deliver economic value.

What is Brooke Story's net worth?: The estimated net worth of Brooke Story is at least $604.28 thousand as of September 4th, 2026. Story owns 7,488 shares of LivaNova stock worth more than $604,282 as of September 9th. This net worth estimate does not reflect any other investments that Story may own. Learn More about Brooke Story's net worth.
How do I contact Brooke Story?: The corporate mailing address for Story and other LivaNova executives is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. LivaNova can also be reached via phone at 442033250660 and via email at [email protected]. Learn More on Brooke Story's contact information.
Has Brooke Story been buying or selling shares of LivaNova?: Within the last three months, Brooke Story has sold $187,266.00 in LivaNova stock. Most recently, Brooke Story sold 2,300 shares of the business's stock in a transaction on Friday, September 4th. The shares were sold at an average price of $81.42, for a transaction totalling $187,266.00. Following the completion of the sale, the director now directly owns 7,488 shares of the company's stock, valued at $609,672.96. Learn More on Brooke Story's trading history.
Who are LivaNova's active insiders?: LivaNova's insider roster includes Francesco Bianchi (Director), Marco Dolci (SVP), Damien McDonald (CEO), Daniel Moore (Director), Alfred Novak (Director), and Brooke Story (Director). Learn More on LivaNova's active insiders.
Are insiders buying or selling shares of LivaNova?: During the last year, insiders at the sold shares 3 times. They sold a total of 5,750 shares worth more than $455,154.00. The most recent insider tranaction occured on September, 4th when Director Brooke Story sold 2,300 shares worth more than $187,266.00. Insiders at LivaNova own 0.4% of the company. Learn More about insider trades at LivaNova.
Information on this page was last updated on 9/4/2026.

Brooke Story Insider Trading History at LivaNova

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/4/2026	Sell	2,300	$81.42	$187,266.00	7,488

Brooke Story Buying and Selling Activity at LivaNova

LivaNova Company Overview

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

Today's Range

Now: $80.70

$80.16

$81.83

50 Day Range

MA: $80.63

$75.78

$85.32

2 Week Range

Now: $80.70

$48.82

$85.76

Volume

472,956 shs

Average Volume

574,157 shs

Market Capitalization

$4.45 billion

P/E Ratio

23.88

Dividend Yield

N/A

Beta

0.87